Inactive Instrument

News Processa Pharmaceuticals Inc Other OTC

Equities

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial	Apr. 11	AQ
Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial	Apr. 11	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference	Mar. 28	AQ
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting	Mar. 25	AQ
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	Feb. 21	AQ
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference	Feb. 14	AQ
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule	Feb. 06	AQ
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering	Feb. 01	AQ
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI	Jan. 30	AQ
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 26	MT
Top Midday Decliners	Jan. 26	MT
Sector Update: Health Care Stocks Higher Friday Afternoon	Jan. 26	MT
Processa Pharmaceuticals Prices $7 Million Common Stock Offering	Jan. 26	MT
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering	Jan. 26	GL
Sector Update: Health Care Stocks Softer Late Afternoon	Jan. 25	MT
Top Midday Gainers	Jan. 25	MT
Processa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer Treatment	Jan. 25	DJ
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses	Jan. 25	AQ
Processa Pharmaceuticals, Inc. Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses	Jan. 25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Processa Pharmaceuticals Inc Other OTC

Equities

Summary

Filters